drugset / Trial / NCT02937662
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
RandomizedParallel-groupOpen-labelTreatment
Summary
In this multi-center, randomized, open-label, prospective clinical trial, a total of 60 relapsed/refractory AML patients will be randomized into 2 groups. In the experimental arm, patients receive IAC regimen. In the control arm, patients receive other physician-directed regimen. The primary end point is complete remission rate.
Timeline
- Start
- 2016-10
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 350 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Idarubicin | Small molecule | 10 mg/m2 | — |
| Comparator | Aclacinomycin | Unknown | — | — |
| Comparator | Daunorubicin | Small molecule | — | — |
| Comparator | Decitabine | Small molecule | — | — |
| Comparator | Fludarabine | Small molecule | — | — |